Predictors of treatment response in bipolar disorders: Evidence from clinical and brain imaging studies

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 3, 2002, Pages 21-25

  Ketter, Terence A ^a   Wang, Po W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; NIMODIPINE; VALPROATE SEMISODIUM;

ARTICLE; BRAIN FUNCTION; CLINICAL FEATURE; DEPRESSION; HUMAN; LIMBIC CORTEX; MANIC DEPRESSIVE PSYCHOSIS; NEUROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CARBAMAZEPINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LITHIUM; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VALPROIC ACID;

EID: 0036125705     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Functional brain imaging, limbic function, and affective disorders
2. Efficacy of divalproex vs lithium and placebo in the treatment of mania
3. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness
4. Treatment of mixed mania
5. Mania: Diagnosis, state measurement and prediction of treatment response
6. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients
7. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder
8. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder
9. Mania: Differential effects of previous depressive and manic episodes on response to treatment
10. The challenge of predicting response to stabilising lithium treatment: The importance of patient selection
11. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders
12. Prediction of affective psychoses response to lithium prophylaxis: The role of socio-demographic, clinical, psychological and biological variables
13. Relationship between the effectiveness of lithium therapy and family history
14. Clinical factors in lithium carbonate prophylaxis failure
15. The course of development of mania in patients with recurrent depression
16. Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate
17. Effects of carbamazepine and lithium on affective disorders
18. Depression during mania: Treatment response to lithium or divalproex
19. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania
20. Lithium treatment of mania: Clinical characteristics, specificity of symptom change, and outcome
21. Sources of lithium resistance in mixed mania
22. Effect of sodium valproate in three patients with organic brain syndromes
23. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders
24. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders
25. A comparison of outcome in adolescent- and later-onset bipolar manic-depressive illness
26. A family study of bipolar I disorder in adolescence: Early onset of symptoms linked to increased familial loading and lithium resistance
27. Comparison of measures used to determine substance abuse in an inpatient psychiatric population
28. An evaluation of the effects of lithium in the treatment of chronic alcoholism, 1: Clinical results
29. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: Prevalence and predictors
30. Lithium-discontinuation-induced refractoriness: Preliminary observations
31. Predictors of valproate response in bipolar rapid cycling
32. A double-blind comparison of valproate and lithium in the treatment of acute mania
33. Divalproex sodium treatment in late adolescent and young adult acute mania
34. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study
35. Divalproex therapy in medication-naive and mood stabilizer-naive bipolar II depression
36. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study
37. Correlates of antimanic response to carbamazepine
38. The manic syndrome: Factors which may predict a patient's response to lithium, carbamazepine and valproate
39. Carbamazepine in rapid cycling bipolar affective disorder
40. Dysphoric mania: Clinical and biological correlates
41. Carbamazepine vs lithium in the treatment and prophylaxis of mania
42. Carbamazepine compared with lithium in the treatment of mania
43. Neuroanatomical models and brain imaging studies
44. Effects of mood and subtype on cerebral glucose metabolism in treatment-refractory bipolar disorders
45. Limbic-cortical dysregulation: A proposed model of depression
46. Relationship of lithium concentrations in the brain measured by lithium-7 magnetic resonance spectroscopy to treatment response in mania
47. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders
48. Baseline hypofrontality and divalproex response in bipolar disorders
49. Cingulate function in depression: A potential predictor of treatment response
50. Plasma GABA predicts acute response to divalproex in mania
51. Baseline cerebral glucose metabolism compared to other potential divalproex response markers
52. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy
53. Cortical GABA reduced in unipolar but not bipolar depressionss
54. 3 Tesla 'H-magnetic resonance spectroscopic (MRS) detection of cerebral gamma-aminobutyric acid (GABA) in bipolar disorder patients and healthy volunteers